论文部分内容阅读
目的 研究血清细胞间粘附分子 1(sICAM 1)在肝细胞肝癌 (HCC)复发前后的变化 ,探讨其在复发监测中的价值。方法 应用酶联免疫分析测定 41例HCC术后复发患者sICAM 1水平 ,并与血清甲种胎儿球蛋白 (AFP)进行同步分析。结果 确诊肝癌复发时 ,所有患者sICAM 1水平均较复发前升高 ,其均值为 (12 89± 317) μg/L。其中 73.2 %的患者sICAM 1>10 0 0 μg/L ,而血清AFP阳性者仅占 6 0 .0 % ,6例AFP阴性复发者sICAM 1较复发前升高 2～ 4倍 ,持续 1～ 4个月后 ,影像学检查才发现肝占位性病变。结论 HCC术后血清sICAM 1水平变化对预测肿瘤复发有一定的临床价值 ,尤其对AFP阴性的患者。
Objective To investigate the changes of serum intercellular adhesion molecule 1 (sICAM 1) before and after the recurrence of hepatocellular carcinoma (HCC) and explore its value in the surveillance of recurrence. Methods The level of sICAM 1 in 41 patients with HCC postoperative recurrence was determined by enzyme - linked immunosorbent assay (ELISA), and the level of serum sICAM - 1 was detected simultaneously with AFP. Results confirmed recurrence of liver cancer, all patients sICAM 1 levels were higher than before relapse, the mean (12 89 ± 317) μg / L. Among them, 73.2% of the patients had sICAM 1> 100 microg / L, while the serum AFP-positive patients only accounted for 60.0%. Six of the 6 patients with AFP-negative recurrence had sICAM 1 2-4 fold more than those before relapse, lasting 1-4 Months later, liver biopsy was only found on imaging studies. Conclusion The change of serum sICAM-1 level after HCC has some clinical value in predicting tumor recurrence, especially in AFP-negative patients.